The
acute phase protein serum amyloid A (SAA) is associated with endothelial dysfunction and early-stage
atherogenesis. Stimulation of vascular cells with SAA increases gene expression of pro-
inflammation cytokines and
tissue factor (TF). Activation of the
transcription factor,
nuclear factor kappa-B (NFκB), may be central to SAA-mediated endothelial cell
inflammation, dysfunction and pro-thrombotic responses, while targeting NFκB with a pharmacologic inhibitor,
BAY11-7082, may mitigate SAA activity. Human carotid artery endothelial cells (HCtAEC) were pre-incubated (1.5 h) with 10 μM
BAY11-7082 or vehicle (control) followed by SAA (10 μg/mL; 4.5 h). Under these conditions gene expression for TF and
Tumor Necrosis Factor (TNF) increased in SAA-treated HCtAEC and pre-treatment with
BAY11-7082 significantly (TNF) and marginally (TF) reduced
mRNA expression. Intracellular TNF and
interleukin 6 (IL-6)
protein also increased in HCtAEC supplemented with SAA and this expression was inhibited by
BAY11-7082. Supplemented
BAY11-7082 also significantly decreased SAA-mediated leukocyte adhesion to
apolipoprotein E-deficient mouse aorta in ex vivo vascular flow studies. In vascular function studies, isolated aortic rings pre-treated with
BAY11-7082 prior to incubation with SAA showed improved endothelium-dependent vasorelaxation and increased vascular cyclic
guanosine monophosphate (cGMP) content. Together these data suggest that inhibition of NFκB activation may protect endothelial function by inhibiting the pro-inflammatory and pro-thrombotic activities of SAA.